EYPT

Business Context and Reporting Period

Company: pSivida Corp. (Note: Request metadata listed "Eyepoint, Inc.", but the filing text identifies the registrant as pSivida Corp.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2010
Business Overview: pSivida develops sustained-release drug delivery products for chronic eye diseases. Its lead product candidate, Iluvien (licensed to Alimera Sciences), received FDA Priority Review for Diabetic Macular Edema (DME) in August 2010. The company also holds licenses for Retisert and Vitrasert with Bausch & Lomb and maintains a research collaboration with Pfizer.

Key Financial Metrics

Note: The filing does not provide explicit gross margin or operating margin percentages; however, the company reported a loss from operations of $(3,435) thousand.

Material Changes vs. Prior Period

• Revenue Decline: Total revenues decreased 86% to $476,000 from $3.383 million. This was primarily due to the completion of the 21.5-month performance obligation period for the Alimera collaboration agreement on December 31, 2009, which had generated significant revenue in the prior year.
• Expense Increase: General and administrative expenses rose 28% to $2.169 million, driven by increased professional fees and stock-based compensation. Research and development expenses remained relatively flat, decreasing slightly by 3% to $1.742 million.
• Derivative Income: The company recorded $338,000 in income from the change in fair value of derivative liabilities (A$-denominated warrants), compared to a $1.519 million expense in the prior year. This swing was due to the spread between the share price and exercise price of the warrants.
• Liquidity Position: Cash and marketable securities increased significantly to $15.3 million, up from $6.0 million in the prior year, largely due to the purchase of $3.5 million in marketable securities during the quarter.

Guidance, Outlook, and Risks

• Outlook: Management anticipates that existing capital resources ($15.3 million) will fund operations into at least calendar year 2012. Future funding beyond that period is substantially dependent on the FDA approval of Iluvien, which would trigger a $25 million milestone payment from Alimera.
• Regulatory Status: Alimera filed a New Drug Application (NDA) for Iluvien in June 2010 and received Priority Review in August 2010. A response from the FDA is expected by the end of calendar year 2010.
• Risks:
  • Failure to obtain FDA approval for Iluvien or other product candidates.
  • Dependence on collaboration partners (Alimera, Pfizer, Bausch & Lomb) for funding and commercialization.
  • Volatility in the fair value of derivative liabilities due to fluctuations in the company's stock price and foreign exchange rates.
  • Potential need for additional capital if milestones are not met or commercialization is delayed.
• Unusual Items: The $338,000 gain on derivatives is a non-cash item resulting from the revaluation of warrants denominated in Australian dollars.

Key Facts for Investor Verification

• FDA Decision Timeline: Verify the status of the FDA's response to the Iluvien NDA, as a decision is expected by the end of 2010. Approval is critical for the anticipated $25 million milestone payment.
• Cash Burn Rate: Confirm the company's ability to sustain operations through 2012 given the net cash used in operating activities of $2.2 million for the quarter.
• Derivative Liability Exposure: Monitor the fair value of the $972,000 derivative liability, which is sensitive to the company's stock price and could result in significant non-cash gains or losses in future periods.
• Revenue Recognition: Understand that future revenue from the Alimera agreement is currently expected to be insignificant absent FDA approval, shifting reliance to milestone payments and royalties.